Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs S&P500 ETF — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B), while S&P500 ETF trades at $777.41 (market cap $819.04B). The key difference: S&P500 ETF is far larger — about 359.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and S&P500 ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| SLS | SPY | |
|---|---|---|
Market Cap | $2.28B | $819.04B |
Volume | 3,128,960 | 30,746,070 |
Sector | Health | — |
52-Week High | $15.46 | $779.14 |
52-Week Low | $1.39 | $631.99 |
Enterprise Value | $2.15B | — |
Typical Hold Time | — | 205 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day. The technical outlook is bullish, with moving averages strongly supportive and the price above key support at $775. However, oscillators are neutral, and the 6-day RSI at 75.74 suggests potential overbought conditions. A dividend of $1.89 is scheduled for payment on October 30, 2026.
The ETF's outlook remains tied to broader S&P 500 earnings, which are projected to grow 35% in 2026 but slow to 15% in 2027. Key risks include market-wide valuation concerns and potential profit growth deceleration. Investor sentiment is mixed, with some analysts highlighting defensive positioning and seasonal patterns favoring a year-end rally.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
